HC Wainwright Lowers Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00

Posted by on Aug 19th, 2026

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) had its price objective reduced by HC Wainwright to $5.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 491.86% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Get Our Latest Analysis on ONCY

Oncolytics Biotech Trading Up 2.7%

NASDAQ:ONCY opened at $0.84 on Wednesday. The company has a market capitalization of $100.83 million, a P/E ratio of -2.48 and a beta of 1.13. The firm has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.92. Oncolytics Biotech has a twelve month low of $0.73 and a twelve month high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). On average, equities research analysts predict that Oncolytics Biotech will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Oncolytics Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new stake in Oncolytics Biotech in the 1st quarter worth about $608,000. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech during the 3rd quarter valued at about $535,000. Connective Capital Management LLC acquired a new position in shares of Oncolytics Biotech during the 4th quarter valued at about $131,000. XTX Topco Ltd purchased a new position in shares of Oncolytics Biotech during the 4th quarter worth about $69,000. Finally, Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech during the 4th quarter worth about $68,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

(Get Free Report)

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.

Featured Articles

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.